Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Shots:

• Sutro to receive $4M as licensing option fee, ~$200M as an option exercise fee, development, regulatory & commercial milestones along with royalties based on sales of STRO-001 in Greater China. BioNova to get STRO-001 from Sutro under clinical & commercial supply agreements
• BioNova gets the option to acquire exclusive rights for the development & commercialization of STRO-001 in Greater China & will lead clinical development, regulatory approval & commercialization of STRO-001 in multiple indications, including NHL, MM & leukemia in the licensed countries
• Sutro will hold development & commercial rights of STRO-001 globally outside of Greater China, including the US

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Linkedin